✦ LIBER ✦

PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

✍ Scribed by K El Ouagari; W Talbot; JF Baladi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN60 Cost Effectiveness of Nilotinib, D

✍ Romero Martin, R.M.; Alvis Nelson, A.N.; De los Ríos Magalí, D.L.R.M.; Chávez Di 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PCN11 COST-UTILITY ANALYSIS OF DASATINIB

✍ JFS Logman; MJ Taylor; K Neumann; L Kutikova; KH Cerri; BA Van Hout; T Kühr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN13 Cost-Effectiveness Analysis of Nil

✍ Niu, X.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN63 The Relative Value of Dasatinib Ve

✍ L. Betegon; I. Gilloteau; P. Martin; A. Woolmore; I. Oyagüez 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN92 Cost-Effectiveness of Nilotinib Ve

✍ R. Yagudina; A. Kulikov; I. Komarov 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN86 Cost-Utility Analysis of Nilotinib

✍ Inocencio, T.J.; Seetasith, A.; Newland, A.; Bose, P.; Holdford, D. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB